Saturday 17 October 2026
Export MLTX’s income statement to Excel — free account
MoonLake Immunotherapeutics
MLTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 3.45%, free cash flow fell 1.89% and total debt rose 35.6%, each against the same quarter a year earlier.
9.55
0.71
−6.92%
Follow MLTX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 10.16 | 9.81 | 4.25 | 10.50 | 37.55 | 5.95 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 11.75 | 13.00 | 15.19 | 63.78 | 64.98 | 62.75 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 2 | 2 | 20 | 50 | 100 | 130 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | — | 0 | (5) | (64) | (44) | (121) | (230) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | 0 | (5) | (65) | (44) | (121) | (230) | |||||
| Depreciation | — | — | — | — | — | 0 | 0 | 0 | 1 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (0.03) | (1.58) | (1.70) | (0.73) | (1.89) | (3.53) | |||||
| Cash flow | — | — | — | — | (0.11) | (0.21) | (1.90) | (0.87) | (1.85) | (3.04) | |||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | — | (0.11) | (0.21) | (1.90) | (0.88) | (1.86) | (3.04) | |||||
| Book value | — | — | — | — | (0.86) | (4.05) | 2.34 | 10.45 | 7.21 | 4.72 | |||||
| Shares, m | — | — | — | — | 3 | 3 | 29 | 49 | 63 | 64 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (56) | (43) | (117) | (196) | ||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | (1) | 0 | |||||
| Free cash flow | — | — | — | — | 0 | (1) | (56) | (43) | (117) | (196) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | (11) | 69 | 504 | 452 | 376 | ||||
| Total debt | — | — | — | — | 0 | 15 | 0 | — | — | 74 | |||||
| Net debt | — | — | — | — | (1) | 7 | (72) | (511) | (448) | (320) | |||||
| Shareholders’ equity | — | — | — | — | (3) | (12) | 69 | 513 | 453 | 304 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | (0.16) | (7.19) | (115.51) | (11.94) | (23.68) | (50.38) | ||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | (1,362.45) | (1,667.26) | 0.00 | |||||
| ROE | — | — | — | — | (0.08) | 63.83 | (175.19) | (12.37) | (24.60) | (59.99) | |||||
Negative figures in brackets.
Charts ten years each
MoonLake Immunotherapeutics vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics, Inc. | $901.0M | — (loss-making) | 4.8× | — | n/m | +33.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| AKTS Aktis Oncology, Inc. | $890.5M | — (loss-making) | — (loss-making) | — | n/m | −12.77% (below 0%: shrinking) | 100.00% | (853.99%) | Compare |
| ANRO Alto Neuroscience, Inc. | $887.7M | — (loss-making) | — | — | n/m | −43.41% (below 0%: shrinking) | — | 0.00% | Compare |
| RIGL Rigel Pharmaceuticals, Inc. | $882.6M | 2.6× | 7.9× | −22.60% (below 0%: shrinking) | −72.07% (below 0%: shrinking) | −229.99% (below 0%: shrinking) | 89.17% | 29.95% | Compare |
| JBIO Jade Biosciences, Inc. | $875.1M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MLTX MoonLake Immunotherapeutics | $873.2M | — (loss-making) | — | — | n/m | −1.89% (below 0%: shrinking) | 0.00% | 0.00% | |
| GLUE Monte Rosa Therapeutics, Inc. | $863.4M | — (loss-making) | — (loss-making) | −61.33% (below 0%: shrinking) | n/m | −34.11% (below 0%: shrinking) | 100.00% | (547.84%) | Compare |
| KURA Kura Oncology, Inc. | $862.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| ALMS Alumis Inc. | $842.4M | — (loss-making) | — (loss-making) | −37.66% (below 0%: shrinking) | n/m | +23.59% (above 0%: growing) | 100.00% | (8,956.38%) | Compare |
| Median of peers | $878.9M | — | — | −30.13% | — | −38.76% | 100.00% | (174.88%) |
MoonLake Immunotherapeutics (MLTX) key facts
- MoonLake Immunotherapeutics (MLTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, MLTX traded at $9.55, a market capitalization of $873.2 million.
- Return on equity was −60.0% and debt-to-equity 0.23.